Health Care

Teladoc Health(NYSE:TDOC) Q4 2022 revenue of $637.7 million, up 15% year-over-year

/ / Health Care /

February 22, 2023 — Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the fourth quarter and full year ended December 31, 2022. the company reported a wider Q4 net loss  of $23.49 per diluted share, Analysts polled by Capital IQ forecast a per-share loss of $0.23. Revenue for the quarter ended Dec. 31 was $637.7 million, Analysts surveyed by Capital IQ projected $633.4 million. For Q1, the company expects a net loss of $0.45 to $0.55 per share on revenue of $610 million to $625 million. Analysts polled by Capital IQ are looking for a per-share loss of $0.42 on revenue of $648.7 million. For 2023, the company said it expects a per-share net loss of $1.25 to $1.75 on revenue of $2.55 billion to $2.68 billion. Analysts surveyed by Capital IQ are expecting a per-share loss of $1.39 and revenue of $2.7

Teladoc Health(NYSE:TDOC) Q4 2022 revenue of $637.7 million, up 15% year-over-year Read Post »

Eli Lilly cuts insulin drug prices by 70%

/ / Health Care /

Eli Lilly announced Wednesday that a 70 percent price cut for its two best-selling insulin products, Humalog and Humulin, will take effect in the fourth quarter. Lilly also said it would reduce the list price of unbranded insulin from $82 to $25 per vial starting May 1, the lowest price for insulin taken by diabetics at mealtime and lower than Lilly’s 1999 Humalog sticker price. Eli Lilly also plans to improve a program that limits out-of-pocket costs to $35 a month for patients.

Eli Lilly cuts insulin drug prices by 70% Read Post »

Morgan Stanley lowered Moderna (NASDAQ:MRNA) price target to $185 from $205

/ / Health Care / ,

Morgan Stanley said in a research note that it lowered its Moderna (NASDAQ:MRNA) price target from $205 to $185 due to increased fees and capital expenditures, while maintaining a “hold” rating. The bank noted that Moderna’s fourth-quarter results were generally in line with expectations. The higher-than-expected guidance of 35%-40% for the cost of main business in 2023 is the most concerned downside factor in the bank’s forecast. Morgan Stanley added that advance filings for personalized cancer vaccines (PCV), flu 2024 and respiratory syncytial virus (RSV) vaccines, as well as a stronger U.S. commercial coronavirus market, are potential short-term upside drivers.

Morgan Stanley lowered Moderna (NASDAQ:MRNA) price target to $185 from $205 Read Post »

Moderna(NASDAQ:MRNA) Q4 2022 revenues of $5.084 billion,down 29.4% year-over-year

/ / Health Care /

February 23, 2023— Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the fourth quarter and fiscal year 2022. Moderna(NASDAQ:MRNA)  reported Q4 earnings of $3.61 per diluted share, Analysts polled by Capital IQ expected $4.75. Moderna(NASDAQ:MRNA)  Revenue for the quarter ended Dec. 31 was $4.86 billion, Analysts surveyed by Capital IQ expected $5.02 billion. Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61。 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12。 Cash used for repurchases of common stock was $3.3 billion for the full year 2022. Business outlook: The Company expects product sales in the first half of 2023 of approximately $2.0 billion. Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses: Full-year expenses

Moderna(NASDAQ:MRNA) Q4 2022 revenues of $5.084 billion,down 29.4% year-over-year Read Post »

Scroll to Top